New HIV Pill Matches Top Treatment in Clinical Trials

People living with HIV may soon have a powerful new treatment option that works just as well as today's leading medications.

Clinical trial results presented at the Conference on Retroviruses and Opportunistic Infections show that an experimental once-daily pill combining doravirine and islatravir matches the effectiveness of Biktarvy, one of the most widely prescribed HIV treatments. The new combination works for both people starting HIV treatment for the first time and those switching from other regimens.

Merck has already submitted the trial data to the Food and Drug Administration. An approval decision is expected in late April 2026.

The two-drug combination represents a shift from the typical three-drug approach to HIV treatment. Doravirine is a next-generation medication that the virus has difficulty developing resistance against. Islatravir is a first-in-class drug that attacks HIV in a novel way.

Development hit a speed bump in 2021 when early trial participants experienced drops in their immune cell counts. Scientists discovered the doses were too high and adjusted accordingly. The lower dose in the new combination pill hasn't shown this side effect.

The switch matters because simpler regimens often mean fewer pills, potentially fewer side effects, and easier adherence for patients managing a lifelong condition.

The Ripple Effect

This approval would add to a growing arsenal of HIV treatments that are becoming increasingly effective and easier to tolerate. Better options mean more people can find a regimen that works for their bodies and lifestyles.

The conference also featured promising research on other long-acting HIV treatments, including experimental twice-yearly options. Together, these advances point toward a future where managing HIV becomes progressively simpler.

For the estimated 1.2 million Americans living with HIV, more choices translate to better health outcomes. When people can stay on treatment comfortably, they maintain undetectable viral loads, which means they can't transmit the virus to others.

Medical advances like this two-drug combination don't just help individual patients. They strengthen public health by making it easier for everyone to access effective, tolerable treatment.

The April decision could mark another milestone in transforming HIV from a devastating diagnosis into a manageable chronic condition.